Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.

about

Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis.[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

P2860

Q40075352-36CA7C49-5D8E-4B5D-AD72-3578E1B5503E Q50076914-DDA3D644-3B71-4874-84C4-97D893A09B12

P2860

Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.

Item

http://www.wikidata.org/entity/Q41667048

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Rituximab use in patients with ...... t on immunological parameters.

@en

type

Item

label

Rituximab use in patients with ...... t on immunological parameters.

@en

prefLabel

Rituximab use in patients with ...... t on immunological parameters.

@en

P1476

Rituximab use in patients with ...... t on immunological parameters.

@en

P2093

E Jancova

http://www.w3.org/2001/XMLSchema#string

H Mareckova

http://www.w3.org/2001/XMLSchema#string

V Bednarova

http://www.w3.org/2001/XMLSchema#string

V Tesar

http://www.w3.org/2001/XMLSchema#string

Z Chocova

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

The dual effects of B cell depletion on antigen-specific T cells in BDC2.5NOD mice.

Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Depletion of functionally active CD20+ T cells by rituximab treatment.

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

The anti-CD20 antibody rituximab reduces the Th17 cell response

P304

107-115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10067-014-2816-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25388644

http://www.w3.org/2001/XMLSchema#string

P921

immunology

Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.

about

P2860

P2860

Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921